CD274 and neoplasm: In support of this consideration, tumor tissue derived from metastatic renal cell carcinoma (mRCC) patients treated with anti-PD-L1 atezolizumab plus bevacizumab was recently found to show an increase in intratumoral CD8 T cells as well as an increase in intratumoral MHC-I, Th1 and T-effector markers, and chemokines.